Get the Stockscreener App
29.86
5.03%
1.43
Mbx Biosciences Inc stock is traded at $29.86, with a volume of 450.32K.
It is up +5.03% in the last 24 hours and up +21.38% over the past month.
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.
See More
Previous Close:
$28.43
Open:
$28.76
24h Volume:
450.32K
Relative Volume:
0.32
Market Cap:
$1.34B
Revenue:
-
Net Income/Loss:
$-47.20M
P/E Ratio:
-19.08
EPS:
-1.5653
Net Cash Flow:
$-43.65M
1W Performance:
-6.60%
1M Performance:
+21.38%
6M Performance:
+178.54%
1Y Performance:
+45.66%
1-Day Range:
$27.93
$30.05
1-Week Range:
$27.86
$33.31
52-Week Range:
$4.8069
$34.83
Mbx Biosciences Inc Stock (MBX) Company Profile
Name
Mbx Biosciences Inc
Sector
Industry
Phone
(317) 989-3100
Address
11711 N. MERIDIAN STREET, CARMEL
Compare MBX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
29.86 | 1.28B | 0 | -47.20M | -43.65M | -1.5653 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-04-25 | Initiated | Goldman | Sell |
| Nov-04-25 | Initiated | TD Cowen | Buy |
| Oct-15-25 | Initiated | Truist | Buy |
| Aug-15-25 | Resumed | Jefferies | Buy |
| Aug-05-25 | Initiated | Mizuho | Outperform |
| Jul-16-25 | Initiated | Oppenheimer | Outperform |
| Apr-10-25 | Initiated | Citizens JMP | Mkt Outperform |
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | JP Morgan | Overweight |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Stifel | Buy |
View All
Mbx Biosciences Inc Stock (MBX) Latest News
EcoR1 Capital LLC Lowers Holdings in MBX Biosciences, Inc. $MBX - MarketBeat
MBX Biosciences (NASDAQ:MBX) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Walleye Capital LLC Increases Stock Holdings in MBX Biosciences, Inc. $MBX - MarketBeat
MBX Biosciences: Testing 2026 May Deliver Another Year Of Share Price Gains - Seeking Alpha
MBX Biosciences, Inc. $MBX Stake Increased by Stempoint Capital LP - MarketBeat
MBX Biosciences (NASDAQ:MBX) Shares Down 5.6%Should You Sell? - MarketBeat
Certain Common Stock of MBX Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025. - marketscreener.com
Certain Stock Options of MBX Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025. - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), MBX Biosciences, Inc. (MBX) and Praxis Precision Medicines (PRAX) - The Globe and Mail
Goldman Sachs initiates coverage of MBX Biosciences (MBX) with sell recommendation - MSN
Goldman Sachs Initiates Coverage of MBX Biosciences (MBX) with Sell Recommendation - Nasdaq
MBX Biosciences (MBX) Is Down 9.7% After Goldman Sell Call and MPM ExitWhat's Changed - Yahoo Finance
Goldman Sachs initiates MBX Biosciences stock with Sell rating on platform concerns - Investing.com Nigeria
Goldman Sachs initiates MBX Biosciences stock with Sell rating on platform concerns By Investing.com - Investing.com South Africa
MBX Biosciences drops 4% in premarket trading after Goldman initiates with sell - MSN
MBX Biosciences initiated with a sell at Goldman Sachs - MSN
Goldman Sachs Initiates Coverage on MBX with Sell Rating | MBX S - GuruFocus
Goldman Sachs Initiates Coverage on MBX Biosciences With Sell Rating, $18 Price Target - marketscreener.com
MBX Biosciences initiated with a Sell at Goldman Sachs - TipRanks
Is MBX Biosciences Inc. stock attractive for growth ETFsJuly 2025 News Drivers & Technical Analysis for Trade Confirmation - Newser
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones - Nasdaq
Sio Capital Management LLC Acquires New Holdings in MBX Biosciences, Inc. $MBX - MarketBeat
How MBX Biosciences Inc. stock benefits from global expansionGold Moves & Growth Focused Stock Pick Reports - Newser
MBX Biosciences (MBX) Stock Analysis Report | Financials & Insights - Benzinga
MBX Biosciences (NASDAQ:MBX) Sets New 12-Month HighHere's What Happened - MarketBeat
Take the Zacks Approach to Beat the Markets: MBX Biosciences, Garrett Motion & Monster Beverage in Focus - MSN
How Much Upside is Left in MBX Biosciences, Inc. (MBX)? Wall Street Analysts Think 80.6% - MSN
MBX Biosciences, Inc. $MBX Shares Purchased by Franklin Resources Inc. - MarketBeat
Rockefeller Capital Management L.P. Acquires Shares of 34,135 MBX Biosciences, Inc. $MBX - MarketBeat
MBX Biosciences (NASDAQ:MBX) Trading Up 5.6%Should You Buy? - MarketBeat
MBX S-8 & SEC Filings - Yahoo Finance Australia
MBX Biosciences Advances Phase 2a Study on PBH Treatment with Imapextide - MSN
Mbx biosciences stock reaches all-time high at 32.16 USD - Investing.com
Mbx biosciences stock reaches all-time high at 32.16 USD By Investing.com - Investing.com Australia
MBX: Once-monthly obesity candidate MBX 4291 shows strong potential for best-in-class tolerability and efficacy - TradingView
Will MBX Biosciences Inc. stock outperform tech sector in 2025Earnings Miss & Low Risk High Reward Ideas - newser.com
Is MBX Biosciences Inc. stock a safe buy before earningsSell Signal & Precise Swing Trade Entry Alerts - newser.com
Will MBX Biosciences Inc. stock rally after Fed decisionsTrade Risk Report & AI Enhanced Trade Execution Alerts - newser.com
MBX Biosciences, Inc. (NASDAQ:MBX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
MBX Biosciences stock maintains Buy rating at Jefferies on strong Phase 2 data By Investing.com - Investing.com South Africa
MBX Biosciences stock maintains Buy rating at Jefferies on strong Phase 2 data - Investing.com Nigeria
Can MBX Biosciences Inc. stock resist sector downturns - newser.com
Will MBX Biosciences Inc. stock remain a Wall Street favorite2025 Technical Patterns & Risk Controlled Daily Trade Plans - newser.com
MBX: Strong clinical progress and funding position drive multiple catalysts in endocrine and metabolic pipeline - TradingView
MBX: Strong clinical progress and funding drive late-stage catalysts in endocrine and metabolic programs - TradingView
Mbx Biosciences Inc Stock (MBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):